drugset / Trial / NCT05422508
Evaluate the Safety and Immunogenicity After MG1111(BARICELA Inj.) as 2nd Vaccination in 4 ~ 6 Year Old Healthy Children With a History of 1st Varicella Vaccination
RandomizedParallel-groupTriple-blindOther
Summary
* Primary objective is to assess the safety of MG1111 until Day 42 using as 2nd vaccination * Secondary objective to assess the immunogenicity and safety of MG1111 using as 2nd vaccination
Timeline
- Start
- 2022-07-05
- Primary completion
- 2025-06
- Completion
- 2027-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MG1111 | Vaccine | 0.5 ml | Subcutaneous |
| Comparator | Suduvax | Unknown | 0.5 ml | Subcutaneous |
| Comparator | Varivax | Vaccine | 0.5 ml | Subcutaneous |